Patrick A Kupelian
Overview
Explore the profile of Patrick A Kupelian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
3556
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu T, Luterstein E, Neilsen B, Goldman J, Garon E, Lee J, et al.
JAMA Oncol
. 2024 Jan;
10(3):352-359.
PMID: 38206614
Importance: Intrathoracic progression remains the predominant pattern of failure in patients treated with concurrent chemoradiation followed by a consolidation immune checkpoint inhibitor for locally advanced, unresectable non-small cell lung cancer...
2.
Faustino F, Altei W, Canton H, Morato L, Jorge de Paula L, Salvador G, et al.
Pract Radiat Oncol
. 2022 Apr;
12(4):e286-e295.
PMID: 35462055
Purpose: This study evaluated the toxicity associated with a short course dose-escalated hypofractionated radiation therapy (HFRT) using image guided RT with or without androgen suppression therapy in patients with prostate...
3.
Kishan A, Steigler A, Denham J, Zapatero A, Guerrero A, Joseph D, et al.
JAMA Oncol
. 2022 Jan;
8(3):e216871.
PMID: 35050303
Importance: Radiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and the required minimum duration of ADT...
4.
Xiang M, Ma T, Savjani R, Pollom E, Karnes R, Grogan T, et al.
JAMA Netw Open
. 2021 Dec;
4(12):e2138550.
PMID: 34902034
Importance: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical...
5.
Kishan A, Karnes R, Romero T, Wong J, Motterle G, Tosoian J, et al.
JAMA Netw Open
. 2021 Jul;
4(7):e2115312.
PMID: 34196715
Importance: The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown. Objective: To compare clinical outcomes among patients with high-risk prostate cancer after definitive treatment....
6.
Philipson R, Romero T, Wong J, Stish B, Dess R, Spratt D, et al.
Eur Urol
. 2021 May;
80(2):142-146.
PMID: 33985797
The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM)...
7.
Ma T, Gafita A, Shabsovich D, Juarez J, Grogan T, Thin P, et al.
Eur Urol Oncol
. 2021 Feb;
5(1):100-103.
PMID: 33602654
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is an emerging imaging modality with greater sensitivity and specificity over conventional imaging for prostate cancer (PCa) staging. Using data...
8.
van Dams R, Jiang N, Fuller D, Loblaw A, Jiang T, Katz A, et al.
Int J Radiat Oncol Biol Phys
. 2021 Jan;
110(3):731-737.
PMID: 33493615
Purpose: To explore the efficacy and toxicity of stereotactic body radiation therapy (SBRT) in high-risk prostate cancer (HRPCa) in a consortium of 7 institutional phase 2 trials and prospective registries....
9.
Levin-Epstein R, Jiang N, Wang X, Upadhyaya S, Collins S, Suy S, et al.
Radiother Oncol
. 2020 Oct;
154:207-213.
PMID: 33035622
Background And Purpose: The optimal dose for prostate stereotactic body radiotherapy (SBRT) is still unknown. This study evaluated the dose-response relationships for prostate-specific antigen (PSA) decay and biochemical recurrence (BCR)...
10.
Levin-Epstein R, Cook R, Wong J, Stock R, Demanes D, Collins S, et al.
Radiother Oncol
. 2020 Jul;
151:26-32.
PMID: 32663537
Background And Purpose: Stereotactic body radiation therapy (SBRT), low dose rate brachytherapy (LDR-BT) and high dose rate brachytherapy (HDR-BT) are ablative-intent radiotherapy options for prostate cancer (PCa). These vary considerably...